“By making it possible to eventually test thousands of designs simultaneously, we can generate unprecedented data on the in vivo targeting behavior of our drug candidates and significantly change the clinical risk equation.” “We are using our in vivo design engine in several internal programs while continuing to invest in scaling our platform,” said co-founder and CSO Pierce Ogden, PhD. Using this platform, the company has initiated several internal programs focused in oncology. Since raising $5.4 million in seed funding in 2020 led by Playground Global, Manifold Bio has advanced their novel protein barcoding technology, the foundation for their in vivo discovery platform and other pooled measurement capabilities. By bringing high-throughput in vivo measurement into the earliest phases of drug development, Manifold Bio is positioned to unlock the full potential of a whole class of protein therapeutics that we call targeted effectors - drugs like cell engagers and ADCs (antibody drug conjugates) where a powerful effect is driven to a precise location by an engineered targeting domain.” “This comes from fundamental limitations of the current paradigm of protein therapeutics development, where engineering of these targeted drugs is largely decoupled from the complex mammalian environment they are meant to navigate. “Despite a growing understanding of surface targets of diseased cells and the promise of new complex antibody formats, drug programs continue to face significant clinical challenges, including major dose limiting toxicities caused by imprecise targeting,” said Manifold Bio co-founder and CEO Gleb Kuznetsov, PhD. The company is pursuing a pipeline of targeting-enhanced protein therapeutics, powered by a platform that features massively parallel in vivo testing of protein therapeutic designs. The investment will enable Manifold Bio to advance its internal drug programs and expand its next-generation protein engineering platform to support additional programs and partnerships.įounded by Professor George Church, PhD, and leading biological engineers from his laboratory at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering, Manifold Bio’s mission is to leverage technological innovation to address key translational bottlenecks in drug creation. Existing investors Playground Global, Fifty Years, and FAST by GETTYLAB also participated. BOSTON-( BUSINESS WIRE)- Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing round led by Triatomic Capital and joined by new investors Section 32, FPV Ventures, Horizons Ventures, and Tencent.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |